120 related articles for article (PubMed ID: 34018505)
21. Mapping the heterogeneity of protein corona by ex vivo magnetic levitation.
Ashkarran AA; Dararatana N; Crespy D; Caracciolo G; Mahmoudi M
Nanoscale; 2020 Jan; 12(4):2374-2383. PubMed ID: 31960871
[TBL] [Abstract][Full Text] [Related]
22. Personalized disease-specific protein corona influences the therapeutic impact of graphene oxide.
Hajipour MJ; Raheb J; Akhavan O; Arjmand S; Mashinchian O; Rahman M; Abdolahad M; Serpooshan V; Laurent S; Mahmoudi M
Nanoscale; 2015 May; 7(19):8978-94. PubMed ID: 25920546
[TBL] [Abstract][Full Text] [Related]
23. The biomolecular corona of nanoparticles in circulating biological media.
Pozzi D; Caracciolo G; Digiacomo L; Colapicchioni V; Palchetti S; Capriotti AL; Cavaliere C; Zenezini Chiozzi R; Puglisi A; Laganà A
Nanoscale; 2015 Sep; 7(33):13958-66. PubMed ID: 26222625
[TBL] [Abstract][Full Text] [Related]
24. Activation of JNK and p38 MAPK Mediated by ZDHHC17 Drives Glioblastoma Multiforme Development and Malignant Progression.
Chen X; Hao A; Li X; Ye K; Zhao C; Yang H; Ma H; Hu L; Zhao Z; Hu L; Ye F; Sun Q; Zhang H; Wang H; Yao X; Fang Z
Theranostics; 2020; 10(3):998-1015. PubMed ID: 31938047
[No Abstract] [Full Text] [Related]
25. Drug delivery approaches for the treatment of glioblastoma multiforme.
Fakhoury M
Artif Cells Nanomed Biotechnol; 2016 Sep; 44(6):1365-73. PubMed ID: 26046399
[TBL] [Abstract][Full Text] [Related]
26. Identification of putative serum glycoprotein biomarkers for human lung adenocarcinoma by multilectin affinity chromatography and LC-MS/MS.
Heo SH; Lee SJ; Ryoo HM; Park JY; Cho JY
Proteomics; 2007 Dec; 7(23):4292-302. PubMed ID: 17963278
[TBL] [Abstract][Full Text] [Related]
27. Human tissue engineering allows the identification of active miRNA regulators of glioblastoma aggressiveness.
Cosset E; Petty T; Dutoit V; Tirefort D; Otten-Hernandez P; Farinelli L; Dietrich PY; Preynat-Seauve O
Biomaterials; 2016 Nov; 107():74-87. PubMed ID: 27614160
[TBL] [Abstract][Full Text] [Related]
28. Nanoformulations for glioblastoma multiforme: a new hope for treatment.
Ortiz R; Cabeza L; Perazzoli G; Jimenez-Lopez J; García-Pinel B; Melguizo C; Prados J
Future Med Chem; 2019 Sep; 11(18):2459-2480. PubMed ID: 31544490
[TBL] [Abstract][Full Text] [Related]
29. [Rare clinical form of glioblastoma multiforme].
Ejma M; Waliszewska-Prosół M; Hofman A; Bladowska J; Zub LW; Podemski R
Postepy Hig Med Dosw (Online); 2014 Mar; 68():316-24. PubMed ID: 24864082
[TBL] [Abstract][Full Text] [Related]
30. Serum amyloid A1 in combination with integrin αVβ3 increases glioblastoma cells mobility and progression.
Lin CY; Yang ST; Shen SC; Hsieh YC; Hsu FT; Chen CY; Chiang YH; Chuang JY; Chen KY; Hsu TI; Leong WC; Su YK; Lo WL; Yeh YS; Patria YN; Shih HM; Chang CC; Chou SY
Mol Oncol; 2018 May; 12(5):756-771. PubMed ID: 29603594
[TBL] [Abstract][Full Text] [Related]
31. In Situ Characterization of Protein Adsorption onto Nanoparticles by Fluorescence Correlation Spectroscopy.
Shang L; Nienhaus GU
Acc Chem Res; 2017 Feb; 50(2):387-395. PubMed ID: 28145686
[TBL] [Abstract][Full Text] [Related]
32. Analysis of temporally evolved nanoparticle-protein corona highlighted the potential ability of gold nanoparticles to stably interact with proteins and influence the major biochemical pathways in Brassica juncea.
Prakash S; Deswal R
Plant Physiol Biochem; 2020 Jan; 146():143-156. PubMed ID: 31751914
[TBL] [Abstract][Full Text] [Related]
33. Protein corona mitigates the cytotoxicity of graphene oxide by reducing its physical interaction with cell membrane.
Duan G; Kang SG; Tian X; Garate JA; Zhao L; Ge C; Zhou R
Nanoscale; 2015 Oct; 7(37):15214-24. PubMed ID: 26315610
[TBL] [Abstract][Full Text] [Related]
34. Time-dependent study of graphene oxide-trypsin adsorption interface and visualization of nano-protein corona.
Kumari S; Sharma P; Ghosh D; Shandilya M; Rawat P; Hassan MI; Moulick RG; Bhattacharya J; Srivastava C; Majumder S
Int J Biol Macromol; 2020 Nov; 163():2259-2269. PubMed ID: 32961193
[TBL] [Abstract][Full Text] [Related]
35. Potential clinical applications of the personalized, disease-specific protein corona on nanoparticles.
García Vence M; Chantada-Vázquez MDP; Vázquez-Estévez S; Manuel Cameselle-Teijeiro J; Bravo SB; Núñez C
Clin Chim Acta; 2020 Feb; 501():102-111. PubMed ID: 31678275
[TBL] [Abstract][Full Text] [Related]
36. Screening for serological biomarkers of pancreatic cancer by two-dimensional electrophoresis and liquid chromatography-tandem mass spectrometry.
Wang Y; Kuramitsu Y; Yoshino S; Takashima M; Zhang X; Ueno T; Suzuki N; Oka M; Nakamura K
Oncol Rep; 2011 Jul; 26(1):287-92. PubMed ID: 21519797
[TBL] [Abstract][Full Text] [Related]
37. Prior malignancies in patients harboring glioblastoma: an institutional case-study of 2164 patients.
Zacharia BE; DiStefano N; Mader MM; Chohan MO; Ogilvie S; Brennan C; Gutin P; Tabar V
J Neurooncol; 2017 Sep; 134(2):245-251. PubMed ID: 28551847
[TBL] [Abstract][Full Text] [Related]
38. Identification of differentially expressed proteins in human glioblastoma cell lines and tumors.
Zhang R; Tremblay TL; McDermid A; Thibault P; Stanimirovic D
Glia; 2003 Apr; 42(2):194-208. PubMed ID: 12655603
[TBL] [Abstract][Full Text] [Related]
39. Serum GFAP is a diagnostic marker for glioblastoma multiforme.
Jung CS; Foerch C; Schänzer A; Heck A; Plate KH; Seifert V; Steinmetz H; Raabe A; Sitzer M
Brain; 2007 Dec; 130(Pt 12):3336-41. PubMed ID: 17998256
[TBL] [Abstract][Full Text] [Related]
40. A systematic review of multifocal and multicentric glioblastoma.
Li Y; Zhang ZX; Huang GH; Xiang Y; Yang L; Pei YC; Yang W; Lv SQ
J Clin Neurosci; 2021 Jan; 83():71-76. PubMed ID: 33358091
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
